PROKIDNEY CORP (PROK) Stock Overview
USA - NASDAQ:PROK - US74291D1046 - Common Stock
PROK Key Statistics, Chart & Performance
The current stock price of PROK is 2.9263 USD. In the past month the price increased by 29.84%. In the past year, price increased by 107.74%.
PROK Latest News, Press Relases and Analysis
PROK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.43 | 400.99B | ||
| AMGN | AMGEN INC | 13.3 | 156.18B | ||
| GILD | GILEAD SCIENCES INC | 15.41 | 148.01B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.66 | 107.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.20B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.83 | 66.90B | ||
| ARGX | ARGENX SE - ADR | 89.29 | 50.63B | ||
| INSM | INSMED INC | N/A | 34.73B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.05 | 34.44B | ||
| NTRA | NATERA INC | N/A | 26.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.28B | ||
| BIIB | BIOGEN INC | 9.32 | 21.87B |
Related stock screener links
About PROK
Company Profile
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The firm is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, rilparencel, is designed to preserve kidney function in a CKD patient’s diseased kidneys. Rilparencel is a product that includes autologous selected renal cells (SRCs) prepared from a patient’s own (autologous) kidney cells. Rilparencel is an investigational product that includes a mixture of kidney cells prepared from the participant’s own kidney tissue. The SRC are formulated rilparencel for reinjection into the patient’s kidneys using a minimally invasive outpatient procedure that is repeatable, if necessary. The company is conducting a global Phase III development program and multiple Phase II clinical trials for rilparencel in subjects with moderate to severe CKD and diabetes.
Company Info
PROKIDNEY CORP
2000 Frontis Plaza Blvd., Suite 250
Winston-Salem NORTH CAROLINA US
Employees: 204
Phone: 13369997028
PROKIDNEY CORP / PROK FAQ
What does PROKIDNEY CORP do?
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The firm is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, rilparencel, is designed to preserve kidney function in a CKD patient’s diseased kidneys. Rilparencel is a product that includes autologous selected renal cells (SRCs) prepared from a patient’s own (autologous) kidney cells. Rilparencel is an investigational product that includes a mixture of kidney cells prepared from the participant’s own kidney tissue. The SRC are formulated rilparencel for reinjection into the patient’s kidneys using a minimally invasive outpatient procedure that is repeatable, if necessary. The company is conducting a global Phase III development program and multiple Phase II clinical trials for rilparencel in subjects with moderate to severe CKD and diabetes.
Can you provide the latest stock price for PROKIDNEY CORP?
The current stock price of PROK is 2.9263 USD. The price decreased by -9.12% in the last trading session.
Does PROK stock pay dividends?
PROK does not pay a dividend.
How is the ChartMill rating for PROKIDNEY CORP?
PROK has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for PROKIDNEY CORP?
PROKIDNEY CORP (PROK) operates in the Health Care sector and the Biotechnology industry.
When does PROKIDNEY CORP (PROK) report earnings?
PROKIDNEY CORP (PROK) will report earnings on 2025-11-10.
Who owns PROKIDNEY CORP?
You can find the ownership structure of PROKIDNEY CORP (PROK) on the Ownership tab.
PROK Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PROK. When comparing the yearly performance of all stocks, PROK is one of the better performing stocks in the market, outperforming 92.71% of all stocks.
PROK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PROK. While PROK seems to be doing ok healthwise, there are quite some concerns on its profitability.
PROK Financial Highlights
Over the last trailing twelve months PROK reported a non-GAAP Earnings per Share(EPS) of -0.57. The EPS increased by 3.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.48% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PROK Forecast & Estimates
14 analysts have analysed PROK and the average price target is 5.95 USD. This implies a price increase of 103.33% is expected in the next year compared to the current price of 2.9263.